Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00108797
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2005-04-18
Brief Title:
Trial of NovoSeven in Haemophilia - Joint Bleeds
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
NovoSeven rFVIIa by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors A Pilot Double-Blind Study Versus Standard Multiple Doses of NovoSeven and Open-Label FEIBA
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in the United States of America USA This study compares the effectiveness and safety of NovoSeven to FEIBA FEIBA VH in haemophilia patients with inhibitors being treated for joint bleeds
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None